Turkish Journal of Gastroenterology
Original Article

Glutathione and glutathione S-transferase levels in patients with liver metastases of colorectal cancer and other hepatic disorders

1.

Center of Radiation and Medical Oncology, National Cancer Institute, Vilnius, Lithuania

2.

Laboratory of Cancerogenesis and Cancer Epidemiology, National Cancer Institute, Vilnius, Lithuania

3.

Clinic of Anaesthesiology and Intensive Care, Vilnius University Faculty of Medicine, Vilnius, Lithuania

4.

Department of Physiology, Biochemestry, Microbiology and Laboratory Medicine, Vilnius University Faculty of Medicine, Vilnius, Lithuania

5.

Republican Vilnius University Hospital, Vilnius, Lithuania

6.

Center of Radiation and Medical Oncology, National Cancer Institute and Clinic of internal Diseases, Family Medicine and Oncology, Vilnius University Faculty of Medicine, Vilnius, Lithuania

7.

Clinic of internal Diseases, Family Medicine and Oncology, Vilnius University Faculty of Medicine and Center of Research, National Cancer Institute, Vilnius, Lithuania

Turk J Gastroenterol 2016; 27: 336-341
DOI: 10.5152/tjg.2016.15457
Read: 115 Downloads: 16 Published: 25 July 2019

Abstract

Background/Aims: Glutathione and glutathione S-transferases (GST) are involved in cell defence against reactive oxygen species, which induces oxidative stress and are associated with different chronic diseases. The aim of the present study was to determine the differences in reduced glutathione (GSH) and GST levels in patients with different liver diseases.

 

Materials and Methods: Overall, 114 patients were enrolled in this study: 58 patients with colorectal cancer (18 without and 40 with liver metastases), 27 with liver steatosis, 29 with alcoholic cirrhosis and a group of 40 healthy volunteers. The levels of GSH and GST in blood serum were evaluated by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s guidelines.

 

Results: Significant differences in GSH and GST levels were observed in most of the groups compared to the healthy volunteers (GSH: 52.72 µg/mL, GST: 0.53 ng/mL): with hepatic steatosis (GSH: 17.04 µg/mL, p<0.001; GST: 5.89 ng/mL, p<0.001), alcoholic cirrhosis (GSH: 62.04 µg/mL, p<0.003; GST: 0.94 ng/mL, p<0.001) and liver metastases (GSH: 37.84 µg/mL, p<0.001, GST: 1.25 ng/mL, p=0.747).

 

Conclusion: The different GSH and GST levels in patients with colorectal cancer liver metastases, liver steatosis and alcoholic cirrhosis indicate the differences in antioxidative system damage and its compensatory possibilities and could serve as potential biomarkers for its correction.

Files
EISSN 2148-5607